Astellas Pharma Inc (OP: ALPMY )

15.26 USD +0.33 (+2.21%)

Official Closing Price Updated: 3:46 PM EDT, May 13, 2021 Add to My Watchlist

Price and Volume

Volume	94,541
Open	15.05
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	14.93
Today's Range	15.05 - 15.28
52wk Range	13.41 - 18.43
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Japan's Ministry of Health, Labour and Welfare Grants Priority Review for Enfortumab Vedotin New Drug Application

Today 20:00 EDT

NDA, submitted in March, is for locally advanced or metastatic urothelial cancer that has progressed after anti-cancer medication

Astellas' XTANDI™ (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer

May 04, 2021

Enzalutamide is now the only oral therapy approved by the European Commission to treat three distinct types of advanced prostate cancer

Performance

YTD	-1.23%	-1.23%
1 Month	+0.79%	+0.79%
3 Month	-10.18%	-10.18%
6 Month	-1.48%	-1.48%
1 Year	-7.74%	-7.74%

More News

Astellas and Seagen Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer

April 19, 2021

Astellas' XOSPATA® (gilteritinib) Meets Overall Survival Endpoint in COMMODORE Trial of Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

March 29, 2021

Astellas Garners New Indication & New Product Formulation Approvals From U.S. FDA for Children with Neurogenic Detrusor Overactivity (NDO)

March 26, 2021

Astellas Receives Positive CHMP Opinion for XTANDI™ (enzalutamide) for Patients with Metastatic Hormone-Sensitive Prostate Cancer

March 26, 2021

European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin

March 26, 2021

Astellas Announces Positive Topline Results from Two Phase 3 Pivotal Global Trials of Fezolinetant for the Nonhormonal Treatment of Vasomotor Symptoms in Postmenopausal Women

February 19, 2021

Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer

February 18, 2021

Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer

February 12, 2021

Astellas and Seagen Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplat

February 12, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.